Bayesian Capital Management’s Celgene Corp CELG Stock Holding History

Bayesian Capital Management’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25,067	Closed	-$2.37M	–	762
2019 Q1	$2.37M	Buy	25,067 +20,267	+422%	+$1.77M	0.45%	55
2018 Q4	$308K	Buy	4,800 +1,391	+41%	+$103K	0.06%	408
2018 Q3	$305K	Sell	3,409 -24,900	-88%	-$2.2M	0.05%	452
2018 Q2	$2.25M	Buy	+28,309	New	+$2.35M	0.51%	35
2017 Q1	–	Sell	-16,600	Closed	-$1.92M	–	832
2016 Q4	$1.92M	Buy	16,600 +8,400	+102%	+$935K	0.48%	21
2016 Q3	$857K	Buy	+8,200	New	+$887K	0.56%	37

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bayesian Capital Management's CELG Position: Q2 2019 in Review

Bayesian Capital Management sold out of Celgene Corp (CELG) in Q2 2019, closing a stake of 25,067 shares — an estimated $2.37M sold.

Bayesian Capital Management first reported a position in CELG in Q3 2016 and held it in 6 quarters. The position peaked at $2.37M in Q1 2019. 1,287 funds tracked by Wall St. Rank hold CELG as of Q2 2019.

Bayesian Capital Management reported no remaining Celgene Corp position as of Q2 2019 after selling out during the quarter.
Bayesian Capital Management sold 25,067 Celgene Corp shares in Q2 2019, an estimated $2.37M.
Bayesian Capital Management first reported a position in Celgene Corp in Q3 2016 and held it in 6 quarters.
Bayesian Capital Management's Celgene Corp position peaked at $2.37M in Q1 2019.
1,287 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2019.

Based on Bayesian Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.